Pharmacy, Health Sciences, & Exercise Science
Retrospective Review of Ursodiol Use in a Community Based Hematopoietic Cell Transplant Center
Document Type
Oral Presentation
Location
Indianapolis, IN
Start Date
13-4-2018 3:45 PM
End Date
13-4-2018 4:15 PM
Sponsor
Chad Knoderer (Butler University)
Description
Hepatic veno-occlusive disease (VOD) is a complication that can develop following hematopoietic stem cell transplantation (SCT). Development of VOD may include multiorgan dysfunction, and severe VOD can lead to death. Incidence of VOD has been reported in up to 50% of SCT patients. Currently, there is no completely effective treatment or standard prophylaxis regimen. As reported in previously published studies, prophylactic ursodiol may be effective in reducing risk of VOD for bone marrow transplant (BMT) patients. This study will assess the efficacy of ursodiol as prophylaxis against VOD for allogeneic BMT patients. The primary objective is to determine the incidence of VOD in allogeneic BMT patients who received ursodiol compared to allogeneic BMT patients who did not receive ursodiol. The secondary objective is to determine 100-day survival and 1-year survival for allogeneic BMT patients who received ursodiol compared to allogeneic BMT patients who did not receive ursodiol. This is a retrospective, single center cohort study. All patients who underwent allogeneic BMT during the period from March 1, 2011 to March 1, 2016 at Franciscan Health were reviewed for inclusion in this study. Patients who died prior to completion of the stem cell transplant chemotherapy preparative regimen were excluded. Patients will be categorized into two groups; those who received ursodiol prior to allogeneic BMT and those who did not receive ursodiol prior to allogeneic BMT. Data analysis is in progress; full data will be presented.
Retrospective Review of Ursodiol Use in a Community Based Hematopoietic Cell Transplant Center
Indianapolis, IN
Hepatic veno-occlusive disease (VOD) is a complication that can develop following hematopoietic stem cell transplantation (SCT). Development of VOD may include multiorgan dysfunction, and severe VOD can lead to death. Incidence of VOD has been reported in up to 50% of SCT patients. Currently, there is no completely effective treatment or standard prophylaxis regimen. As reported in previously published studies, prophylactic ursodiol may be effective in reducing risk of VOD for bone marrow transplant (BMT) patients. This study will assess the efficacy of ursodiol as prophylaxis against VOD for allogeneic BMT patients. The primary objective is to determine the incidence of VOD in allogeneic BMT patients who received ursodiol compared to allogeneic BMT patients who did not receive ursodiol. The secondary objective is to determine 100-day survival and 1-year survival for allogeneic BMT patients who received ursodiol compared to allogeneic BMT patients who did not receive ursodiol. This is a retrospective, single center cohort study. All patients who underwent allogeneic BMT during the period from March 1, 2011 to March 1, 2016 at Franciscan Health were reviewed for inclusion in this study. Patients who died prior to completion of the stem cell transplant chemotherapy preparative regimen were excluded. Patients will be categorized into two groups; those who received ursodiol prior to allogeneic BMT and those who did not receive ursodiol prior to allogeneic BMT. Data analysis is in progress; full data will be presented.